Anthony George Creber

The court issued trial management directions and an endorsement, adjourning a bifurcated liability trial scheduled to commence on May 21, 2019.

The adjournment was necessitated by the parties' lack of trial readiness, specifically concerning the plaintiff's uncertainty regarding witness identities (over 20 potential witnesses, some unnamed) and the failure to finalize an agreed statement of facts.

Additionally, the plaintiff's last-minute motion to add another foreign defendant, Eli Lilly S.A., introduced unresolved jurisdictional issues that would further complicate and extend the trial.

The court emphasized the importance of efficient trial management and the fair allocation of judicial resources, concluding that proceeding with the trial under these circumstances would risk exceeding the allotted time and prejudice other litigants.

Apotex appealed a prohibition order preventing the Minister of Health from issuing a notice of compliance for its generic version of Plavix.

Apotex alleged that Sanofi's selection patent for clopidogrel bisulfate was invalid on the grounds of anticipation, obviousness, and double patenting.

The Supreme Court of Canada dismissed the appeal, clarifying the tests for anticipation and obviousness in Canadian patent law.

The Court adopted a two-step approach for anticipation (prior disclosure and enablement) and a four-step approach for obviousness, including a flexible 'obvious to try' consideration.

The Court found the selection patent was not anticipated, not obvious, and did not constitute double patenting.

The appellant developed a cancer-fighting drug containing paclitaxel, a medicine in the public domain.

The respondent held patents for specific formulations and uses of paclitaxel.

The appellant applied for a Notice of Compliance (NOC) as a new drug, not relying on the respondent's data.

The Minister issued the NOC.

The respondent sought to quash the NOC, arguing that under s. 5(1.1) of the Patented Medicines (Notice of Compliance) Regulations, the mere presence of paclitaxel triggered a statutory freeze.

The Supreme Court of Canada held that s. 5(1.1) does not apply to innovative drugs but is confined to generic copies.

The Minister was entitled to issue the NOC without subjecting the appellant to the statutory freeze.

Novopharm held a compulsory licence for the patented medicine nizatidine, owned by Eli Lilly.

Novopharm and Apotex entered into a supply agreement whereby Novopharm would obtain the medicine and supply it to Apotex.

Eli Lilly sought to terminate Novopharm's licence, arguing the agreement constituted an impermissible sublicence, and sought prohibition orders against the issuance of Notices of Compliance to both Novopharm and Apotex.

The Supreme Court of Canada held that the supply agreement did not constitute a sublicence, as it did not grant Apotex the independent right to exercise Novopharm's licensed rights.

The Court also held that Apotex's proposed reformulation of the bulk medicine into final-dosage form would not infringe Eli Lilly's patents.

The appeals by Novopharm and Apotex were allowed.

The appellant sought a patent for a new soybean variety developed through artificial cross-breeding.

The Commissioner of Patents and the Federal Court of Appeal rejected the application.

On appeal to the Supreme Court of Canada, the Court held that the appellant failed to meet the disclosure requirements under s. 36(1) of the Patent Act.

The specification did not adequately describe the steps involved in the cross-breeding process to allow a person skilled in the art to reproduce the invention.

The Court further held that merely depositing a sample of the seeds did not satisfy the statutory disclosure requirement.

The appeal was dismissed.